BIOTYPE is attending the EHA 2023 congress.
BIOTYPE is excited to announce its attendance at the EHA2023 congress from June 8th to 11th in Frankfurt.
As the largest European-based haematology event, this congress provides a platform for medical professionals, scientists, and researchers to connect, develop professionally, and advance research.
BIOTYPE offers innovative diagnostic solutions for different types of blood cancer, including acute myeloid leukaemia (AML), which is the most common type of leukaemia in adults. Accurate diagnosis of AML subtypes is crucial for effective risk-directed therapy, and our solutions allow the identification of gene fusions that are relevant to the ELN guideline conform classification of AML, as well as solutions for stem cell transplant monitoring.
Visit us at the BIOTYPE booth A116 to learn more about our products and how they can help facilitate optimal diagnostic solutions for your needs.
